Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease?
|
|
- Alan Griffin
- 5 years ago
- Views:
Transcription
1 670 E. Paoletti et al % after dialysis [3]. In contrast to the above findings, Farkouh et al. found that a single HD treatment produced no significant change in the ctni level s diagnostic classification [5]. We found that 94% of patients had stable ctni levels without change in classification after dialysis with a high-flux membrane. Clinically, this is evidence that one does not need to be concerned with the timing of blood sampling in relation to HD when following TnI levels for a patient suspected of having an ACS. Conclusion In conclusion, in asymptomatic ESRD patients, most patients have a normal TnI level but many do have slight elevations in TnI using a new-generation assay. Levels remained stable over a 3-month period in most patients. Very few patients had elevations in the AMI range. HD treatment does not appear to affect the level. The significance of the lowlevel elevations seen in this study will remain unclear until further outcome studies are performed. Conflict of interest statement. None declared. References 1. Apple FS, Murakami MM, Pearce LA et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: Wang AYM, Lai KN. Use of cardiac biomarkers in end stage renal disease. J Am Soc Nephrol 2008; 19: Nephrol Dial Transplant (2011) 26: doi: /ndt/gfq409 Advance Access publication 13 July Wayand D, Baum H, Schatzle G et al. Cardiac troponin T and I in end-stage renal failure. Clin Chem 2000; 46: Lippi G, Tessitore N, Montagnana M et al. Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med 2008; 132: Farkouh ME, Robbins MJ, Zafar MU et al. Association between troponin I levels and mortality in stable hemodialysis patients. Am J Med 2003; 114: Khan NA, Hemmelgarn BR, Tonelli M et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005; 112: Keller T, Zeller T, Peetz D et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361: Reichlin T, Hochholzer W, Bassetti S et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. NEnglJ Med 2009; 361: London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: Conway B, McLaughlin M, Sharp P et al. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic hemodialysis. Nephrol Dial Transplant 2005; 14: Received for publication: ; Accepted in revised form: Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease? Ernesto Paoletti 1, Diego Bellino 1, Anna Maria Gallina 2, Marco Amidone 1, Paolo Cassottana 3 and Giuseppe Cannella 1 1 Divisione di Nefrologia, Dialisi e Trapianto, 2 Dipartimento di Scienze della Salute dell Università and 3 Divisione di Cardiologia, Azienda Ospedaliera Universitaria San Martino, Genova, Italy Correspondence and offprint requests to: Ernesto Paoletti; ernesto.paoletti@hsanmartino.it Abstract Background. The role of cardiovascular factors in predicting renal outcome has not been extensively elucidated. Herein, we report a prospective evaluation of the impact of left ventricular hypertrophy (LVH) on outcome in nondiabetic patients with chronic kidney disease (CKD). Methods. We studied 144 patients (99 men; age 62 ± 14 years) with stage 3 4 CKD, with baseline assessment The Author Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 LVH and CKD progression 671 of left ventricular mass index (LVMi) by echocardiography, estimated glomerular filtration rate (egfr) by MDRD equation, 24-h blood pressure profile and 24-h proteinuria. Combined end point was progression to ESRD requiring dialysis, or death within 5 years. Results. Forty-nine patients (34%) progressed to dialysis, 24 (17%) died, 57 (39%) were dialysis-free after 5 years and 14 were lost to follow-up. Multivariate Cox proportional hazards analysis showed that increased LVMi (HR 1.28, 95% CI for each 10-g/m 2 increase, P < ) and reduced egfr (5% risk increase for each 1-mL/min reduction, P = 0.027) were the significant predictors of the combined end point in stage 3 CKD patients, whereas LVMi proved to be the only significant predictor of the combined end point in patients with stage 4 CKD (HR 1.19, 95% CI , P < ). The same analysis showed that LVMi was the only significant predictor of progression to dialysis in stage 3 CKD patients (HR 1.42, 95% CI for each 10-g/m 2 increase, P < ), while a 20% increase in the risk of progression to ESRD was observed for each 10-g/m 2 increase in LVMi (P < ), and a 10% increase for each 1-mL/min reduction in egfr (P = 0.046) in patients with stage 4 CKD. When evaluating the predictive role of LVMi on outcome using AUC-ROC curves, the overall performance of the model including LVMi (AUC 0.877, 95% CI ) was superior to the model including egfr (AUC 0.737, 95% CI ) for the end point of progression to dialysis (P = 0.026, Hanley test). Conclusions. LVH proved to be the strongest predictor of the risk of progression to dialysis in non-diabetic CKD, especially among patients with less advanced renal dysfunction. Regardless of whether it is a simple marker or a pathogenetic factor, LVH encompasses all factors possibly affecting renal and general outcome in CKD patients. Keywords: chronic kidney disease; dialysis; left ventricular hypertrophy; mortality; outcome Introduction Epidemiological studies have reported a high prevalence of chronic kidney disease (CKD) in the general population since the KDOQI clinical practice guidelines were extensively adopted to identify and classify renal disease [1 3]. Only a minority of CKD patients, however, progress to end-stage renal disease (ESRD) requiring dialysis treatment. The main reason for this may be either the high incidence of CV death in CKD patients before they reach ESRD [4] or the heterogeneity in the risk of progressive renal function worsening due to complex interactions among genetic, environmental and pathogenetic factors [5]. Among these factors, reduced glomerular filtration rate and high urinary albumin excretion were identified as the main predictors of CKD progression to ESRD [6,7]. Furthermore, a recent study showed that combining the two data greatly improved the chances of identifying patients at increased risk of ESRD [8]. However, most studies lack information on many other potentially important risk factors, and especially on cardiovascular ones [9,10]. Establishing reliable and early indexes for identifying patients at high risk of developing ESRD should be a priority in the current effort to establish both clinical practice guidelines and plans for medical and financial management of CKD [5,11]. Therefore, the aim of this study was to evaluate the power of left ventricular hypertrophy (LVH) as compared with traditional risk factors in predicting the combined end point of progression to ESRD requiring renal replacement therapy (RRT), or death in a population of non-diabetic, stage 3 and 4 CKD patients who had previously been evaluated by echocardiography and 24-h ambulatory blood pressure monitoring (ABPM) for left ventricular mass determination and blood pressure profile assessment. Materials and methods Patients and study design Two hundred and forty-four patients from a cohort of 315 consecutive CKD patients who were referred to our renal unit for the first time were considered eligible for our previous study [12]. Exclusion criteria were diabetes in 35 patients, severe ischaemic heart disease or severe valvular disease in 23, inadequate acoustic window for echocardiographic examination in 5, malignancies in 2, and unwillingness to participate in the study in 6. All 244 patients had undergone both 24-h ABPM BP assessment and echocardiographic examination for left ventricular mass index (LVMi) measurement since the aim of our previous study was to assess the prevalence of LVH and its clinical correlate in a population of nondiabetic, CKD subjects [12]. From this historical cohort, we prospectively evaluated the 144 subjects with overt CKD (83 with stage 3 and 61 with stage 4 CKD) who had not yet reached ESRD at the time of the first observation. These patients underwent periodic clinical and biochemical profile evaluation which was scheduled on the basis of baseline CKD stage as well as on renal disease progression rate. The present study was designed with two primary end points, i.e. the combined end point of progression to ESRD requiring RRT or death from all cause, and progression to ESRD requiring RRT, all occurring within 5 years. The study protocol was drawn up according to the Declaration of Helsinki and in keeping with the recommendations issued by the ethical committee of our institution. Each patient gave informed consent. Measurements and definitions Descriptions of both the ABPM and the echocardiographic studies are reported elsewhere [12]. ABPM was performed using Spacelabs (SpaceLabs Inc., Redmond, WA, USA). We derived the average 24-h systolic blood pressure (SBP) and diastolic blood pressure (DBP), the awake SBP and DBP, and the asleep SBP and DBP from the ABPM data. Pulse pressure (PP) was calculated as SBP DBP for each set of BP measurements, either office or ABPM. Dipping was defined as a 10% reduction in night-time ambulatory BP compared with daytime ambulatory BP, whereas reverse dipping was defined as no reduction, or even an increase in night-time ABPM BP compared with daytime values [13]. Arterial hypertension was defined as an average BP 130/80 mmhg according to the criteria issued by the NKF-Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in CKD [14]. On the basis of ABPM records, patients were classified as normotensives, dippers, non-dippers or reverse dippers. Echocardiography was performed on each subject within 1 week either prior to or following ABPM using a two-dimensional guided M-mode echocardiograph according to the American Society of Echocardiography (ASE) recommendations [15]. Left ventricular mass (LVM) was calculated according to the formula, LVM = [(IVS d +PW d +
3 672 E. Paoletti et al. EDD) 3 EDD 3 ] g [16], and then indexed for body surface area (BSA) (LVMi). LVH was defined as LVMi >134 and >110 g/m 2 according to previously reported cut-off values for men and women, respectively [16]. Relative wall thickness (RWT) was calculated as the 2PW/EDD ratio, and a value of 0.44 was taken as the cut-off limit to define concentric (RWT >0.44) or eccentric (RWT 0.44) LVH [17]. The percent fractional shortening (FS) of the LV was calculated as EDD EDS / EDD 100. Systolic dysfunction was defined as an FS value 30%. Depending on whether LVH was present or not, as well as on the different LV geometry and FS value, patients were further divided into four groups, i.e. normal LV, concentric LVH, eccentric LVH and systolic dysfunction [17,18]. Serum creatinine, haemoglobin (Hgb) concentration, serum albumin, cholesterol, triglycerides, uric acid and immunoreactive parathyroid hormone (ipth) as well as 24-h urinary protein excretion rate were measured for each patient at least in triplicate and then averaged. Estimated glomerular filtration rate (egfr) was calculated according to the fourvariable MDRD equation [19]. Statistical analyses Analyses were performed using the statistical package SPSS 13.0 (SPSS, Chicago, IL, USA). A value of P < 0.05 was considered statistically significant. Data are presented as mean ± SD since all continuous variables were normally distributed. Normality of distribution was assessed by the Kolmogorov Smirnov test. The significance of association between each clinical and demographic variable (age, duration of either arterial hypertension or chronic kidney disease at the time of the first observation, number of antihypertensive medications, serum creatinine, Hgb, total cholesterol, triglycerides, serum albumin, ipth, daily urinary protein excretion, and each set of ABPM-derived BP values) was determined by calculating Spearman s correlation coefficient (r). Comparisons between groups were made by the unpaired t-test for continuous variables. Fisher s exact test or the chi-square test, when appropriate, was used for between-group comparisons of categorical variables. Cox proportional hazards analyses were performed to assess the hazard ratio (HR) and 95% CI for the risk of the combined end point of progression to ESRD requiring dialysis or death, and for death-censored risk of progression to dialysis. Both univariate and multivariate models were analysed separately for stage 3 CKD patients and for those with stage 4 CKD. The following independent variables were included in the regression model: age, pulse pressure, egfr, 24-h urinary protein excretion rate Table 1. Baseline demographic and clinical parameters of the study population and LVMi. Kaplan Meier survival analysis was used to establish survival curves for combined end point-free survival and dialysis-free survival. To test the sensitivity and specificity of egfr and of LVMi in predicting both the combined end point and the end point of dialysis, we generated receiver-operating characteristic (ROC) curves, including area under the curve (AUC), and their 95% CI. Test performances for various models, including LVMi, egfr or both, were compared by the Hanley method. Results Of the 144 CKD subjects, 14 (10%) were lost to follow-up due to their moving to other cities or for unknown reasons, 49 (34%) progressed to ESRD requiring RRT within the 5-year observation period, 24 (17%) died, and 57 (39%) were alive and RRT-free at the end of the 5-year follow-up period. Table 1 shows the baseline demographic and clinical data of the study population. No significant differences were found between the 130 patients who were followed up for 5 years and the 14 who were lost to follow-up. At baseline, 24-h PP was directly associated with age (r = 0.56; P < ), 24-h proteinuria (r = 0.19; P = 0.026) and LVMi (r = 0.18; P = 0.022), whereas both 24-h proteinuria and LVMi were inversely associated with egfr (P = and P = 0.045, respectively). Furthermore, a significant inverse association was found between LVMi and FS (P = 0.004). Table 2 shows a comparison analysis of demographic and clinical data between the 73 subjects who reached the combined end point within the 5-year observation period and the 57 subjects who were still alive and dialysis-free at the end of this period. Subjects who were alive at end point had higher egfr and lower baseline LVMi than patients who either had started dialysis or had died in the meantime (both P < , unpaired t-test). Moreover, a higher proportion of subjects reaching the end point of dialysis or death had Age, years (range) 62 (17 76) Gender, M/F (%) 99 (69)/45 (31) Diagnosis of renal disease, GN/TI/HPT/APKD/other (%) 54 (37)/11 (8)/62 (43)/9 (6)/8 (6) egfr, ml/min 32.9 ± 12.3 Stage CKD, 3/4 (%) 83 (58)/61 (42) Hgb, g/dl 11.9 ± 1.8 Serum albumin, g/dl 3.9 ± 0.7 Total cholesterol, mg/dl 229 ± 59 Triglycerides, mg/dl 206 ± 150 Uric acid, mg/dl 7.0 ± 2.3 ipth, pg/ml 82 ± h SBP, mmhg 139 ± h DBP, mmhg 81 ± 9 24-h PP, mmhg 58 ± 14 Dippers/non-dippers/reverse dippers (%) 11 (8)/88 (61)/45 (31) Patients on RAAS blockers/other antihypertensives/statins (%) 46 (32)/101 (70)/68 (47) 24-h urinary protein excretion rate, g/day 1.1 ± 1.78 LVMi, g/m 2 BSA 145 ± 41 FS, % 37.9 ± 8.4 LV geometry, normal/concentric LVH/eccentric LVH/systolic dysfunction (%) 52 (36)/37 (26)/38 (26)/17 (12) Comparison between groups was made by unpaired t-test for continuous variables. Fisher s exact test or the chi-square test, when appropriate, was used for between-group comparison of categorical variables. GN, glomerulonephritis; TI, chronic tubulointerstitial nephropathy; HPT, hypertensive nephropathy; APKD, polycystic kidney disease; egfr, estimated glomerular filtration rate; CKD, chronic kidney disease; Hgb, haemoglobin; ipth, intact parathyroid hormone; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; LVMi, left ventricular mass index; BSA, body surface area; LVH, left ventricular hypertrophy; FS, left ventricular fractional shortening; LVH, left ventricular hypertrophy.
4 LVH and CKD progression 673 Table 2. Comparison between baseline demographic and clinical parameters of 57 CKD patients alive and dialysis-free after 5 years, and 73 CKD patients reaching the combined end point within the 5-year observation period Alive, dialysis-free Combined end point P n Age, years 61 ± ± Gender, M/F 36/21 53/ Diagnosis of renal disease, GN/TI/HPT/APKD/other 18/6/27/3/3 29/5/30/6/ egfr, ml/min 39.4 ± ± 10.8 < Stage CKD, 3/4 45/12 31/42 < Hgb, g/dl 12.3 ± ± Serum albumin, g/dl 3.9 ± ± Total cholesterol, mg/dl 232 ± ± Triglycerides, mg/dl 199 ± ± Uric acid, mg/dl 7.1 ± ± ipth, pg/ml 90 ± ± h SBP, mmhg 138 ± ± h DBP, mmhg 82 ± ± h PP, mmhg 56 ± ± Dippers/non-dippers/reverse dippers 5/35/17 3/43/ Patients on RAAS blockers/other antihypertensives/statins 18/41/26 19/49/ h urinary protein excretion rate, g/day 1.05 ± ± LVMi, g/m 2 BSA 120 ± ± 40 < LVH prevalence, yes/no 18/39 65/8 < FS, % 39.5 ± ± LV geometry, normal/concentric LVH/eccentric LVH/systolic dysfunction 39/8/8/2 8/26/25/14 < stage 4 CKD and greater prevalence of LVH as well as a more unfavourable LV geometric pattern such as eccentric LVH or systolic dysfunction compared with surviving dialysis-free subjects (all P < , Fisher s exact test or chisquare test). In contrast, no significant differences were observed in the two groups regarding age, gender, and the prevalence of arterial hypertension, dipping habit, albuminuria, serum albumin and anaemia. Lastly, higher LVMi (167 ± 41 g/m 2 ) and greater prevalence of stage 4 CKD (65%) were the only significant differences we observed in the 49 patients who reached ESRD and who started dialysis as compared with the 57 subjects who were still alive, dialysis-free after the 5-year observation period (both P < ; unpaired t-test and Fisher s exact test, respectively). Table 3. Cox proportional hazard analysis of the combined end point progression to dialysis or death in 83 stage 3 CKD patients Risk of progression to dialysis or death (combined end point) Univariate Cox regression analysis showed a 27% increase in the risk of the combined end point for each 10-g/m 2 increase in baseline LVMi and a 6% increase for each 1-mL reduction in baseline egfr for patients with stage 3 CKD (Table 3), and an 18% increase for each 10-g/m 2 increase in baseline LVMi and a 9% increase for each 1-mL reduction in egfr in patients with stage 4 CKD (Table 4). Multivariate analysis showed that LVMi (HR 1.28; 95% CI ; P < ) and, to a lesser extent, egfr (HR 0.95; 95% CI ; P = 0.027) were significant predictors of the risk of combined end point in stage 3 CKD patients (data adjusted for age, pulse pressure and proteinuria) (Table 3), whereas LVMi (HR 1.194; 95% Table 4. Cox proportional hazard analysis of the combined end point progression to dialysis or death in 61 stage 4 CKD patients Variable HR (95% CI) P Univariate analysis Age, 1-year increase ( ) 0.32 Proteinuria, 1-g/24 h increase ( ) h PP, 1-mmHg increase ( ) 0.17 egfr, 1-mL/min increase 0.94 ( ) 0.01 LVMi, 10-g/m 2 increase ( ) < Multivariate analysis Age, 1-year increase ( ) 0.21 Proteinuria, 1-g/24 h increase 1.27 ( ) h PP, 1-mmHg increase ( ) 0.26 egfr, 1-mL/min increase ( ) LVMi, 10-g/m 2 increase ( ) < Variable HR (95% CI) P Univariate analysis Age, 1-year increase ( ) 0.71 Proteinuria, 1-g/24 h increase ( ) h PP, 1-mmHg increase ( ) 0.72 egfr, 1-mL/min increase ( ) LVMi, 10-g/m 2 increase ( ) < Multivariate analysis Age, 1-year increase ( ) 0.9 Proteinuria, 1-g/24 h increase ( ) h PP, 1-mmHg increase ( ) 0.45 egfr, 1-mL/min increase ( ) 0.19 LVMi, 10-g/m 2 increase ( ) <0.0001
5 674 E. Paoletti et al. Fig. 1. Kaplan Meier analysis of combined end point-free survival in patients with LVH and in those with normal LVMi at baseline (log-rank P < 0.001). Table 5. Cox proportional hazard analysis of progression to dialysis in 83 stage 3 CKD patients Variable HR (95% CI) P Univariate analysis Age, 1-year increase ( ) 0.77 Proteinuria, 1-g/24 h increase ( ) h PP, 1-mmHg increase ( ) 0.22 egfr, 1-mL/min increase ( ) 0.19 LVMi, 10-g/m 2 increase ( ) < Multivariate analysis Age, 1-year increase ( ) 0.16 Proteinuria, 1-g/24 h increase ( ) hr PP, 1-mmHg increase ( ) 0.22 egfr, 1-mL/min increase 0.96 ( ) 0.26 LVMi, 10-g/m 2 increase 1.42 ( ) < Table 6. Cox proportional hazard analysis of progression to dialysis in 61 stage 4 CKD patients Variable HR (95% CI) P Fig. 2. Kaplan Meier analysis of dialysis-free survival in patients with LVH and in those with normal LVMi at baseline (log-rank P < 0.001). CI ) proved to be the only significant predictor of the combined end point in patients with stage 4 CKD (data adjusted for age, pulse pressure, egfr and proteinuria) (Table 4). Figure 1 shows Kaplan Meier curves for combined end point-free survival in the 144 stage 3 4 CKD patients subdivided according to the presence or absence of LVH at baseline (Figure 1). When evaluating the role of the various baseline LV geometric patterns in predicting the combined end point- Univariate analysis Age, 1-year increase ( ) 0.48 Proteinuria, 1-g/24 h increase ( ) h PP, 1-mmHg increase ( ) 0.78 egfr, 1-mL/min increase ( ) LVMi, 10-g/m 2 increase ( ) < Multivariate analysis Age, 1-year increase 1.02 ( ) 0.23 Proteinuria, 1-g/24 h increase 1.07 ( ) h PP, 1-mmHg increase ( ) 0.66 egfr, 1-mL/min increase ( ) LVMi, 10-g/m 2 increase ( ) Fig. 3. The AUC-ROC curves for combined end point (A) and the end point of progression to dialysis (B) as predicted by a model including LVMi alone, egfr alone or both. Clinical predictors in both models included age, 24-h proteinuria and 24-h pulse pressure.
6 LVH and CKD progression 675 free survival, patients with systolic dysfunction showed the worst survival rate according to Kaplan Meier analysis (P < 0.001, log-rank test). Risk of progression to dialysis Univariate Cox proportional hazards analysis showed that each 10-g/m 2 increase in baseline LVMi was associated with a 28% increase in the risk of progression to ESRD requiring dialysis within the 5-year follow-up period in patients with stage 3 CKD (Table 5), whereas a 19% increase in the HR for each 10-g/m 2 increase in baseline LVMi and a 13% increase for each 1-mL reduction in egfr were observed in patients with stage 4 CKD (Table 6). Multivariate analysis proved that increased LVMi was the only significant predictor of the risk of progression to dialysis in patients with stage 3 CKD (data adjusted for age, egfr, pulse pressure and 24-h urinary protein excretion rate) (Table 5), whereas a 20% increase in the risk for each 10-g/m 2 increase in baseline LVMi and a 10% increase for each 1-mL reduction in egfr were observed in patients with stage 4 CKD (data adjusted for age, pulse pressure and proteinuria) (Table 6). Figure 2 shows Kaplan Meier curves for dialysis-free survival in the 144 CKD patients with and without LVH at baseline (Figure 2). The role of LVMi and egfr in predicting outcome AUC-ROC curves showed that a model, which included both LVMi and egfr, was highly predictive of both the combined end point (AUC 0.854, 95% CI ) and the progression to dialysis (AUC 0.884, 95% CI ) (Figure 3). Moreover, a comparison of the AUC-ROC curves by the Hanley test showed that the model including both LVMi and egfr was more predictive than models including either LVMi or egfr alone in predicting both the combined end point (P = vs LVMi alone and P = vs egfr alone) and the progression to dialysis (P < vs LVMi and P = vs egfr). Lastly, the model including LVMi provided significantly higher sensitivity and specificity than the model with egfr in predicting progression to dialysis (P = 0.026). Discussion Prospective analysis of our historical cohort of non-diabetic CKD patients [12] showed that baseline LVH was the strongest predictor of a composite end point consisting of either ESRD requiring dialysis, or death. LVH has indeed been independently associated with adverse outcome in the general population and in renal patients as well [20 22]. The most relevant and novel finding of our study, however, is that LVH also proved to be the most significant predictor of ESRD requiring RRT, despite the inclusion of egfr values in the Cox proportional hazards model, as well as the only predictor of the progression to dialysis in patients with less advanced CKD. Although we do not present a definite explanation for this finding, we do hypothesize that LVH could be a marker of the risk of renal disease progression towards the end stage because the same pathogenetic factors that are involved in kidney damage are also responsible for the increase in both LV wall thickness and internal dimension. In our cohort, baseline LVH was in fact significantly associated with elevated PP and older age, whereas no associations were shown with egfr, the degree of anaemia, dyslipidaemia, ipth or serum albumin [12]. However, the prevalence of arterial hypertension in our cohort was similar in patients reaching ESRD and in dialysis-free survivors. Moreover, 24-h BP values did not significantly predict the risk of developing ESRD and dialysis, thus ruling out the possibility that inadequate BP control may have played a major role in both cardiac hypertrophy and CKD progression in our patients. Furthermore, cardiac and renal involvement could be the effect of endothelial dysfunction inducing generalized vascular damage in CKD patients, which is consistent with findings from the cohort enrolled in the LIFE Study which demonstrated a significant association of LVH with urinary albumin excretion [23]. Accordingly, a significant association was indeed found in our sample between increased PP, an indirect expression of vascular stiffness, and both LVMi and proteinuria. Recent reports that are consistent with this pathogenetic hypothesis have shown that NT-proBNP and proanp, which are recognized markers of cardiac function impairment, proved to be strong predictors of CKD progression to ESRD in non-diabetic patients [24,25]. LVH might also exert a direct pathogenetic effect on the progression of CKD to ESRD. Reports exist showing that LVH may be associated with subclinical worsening of systolic LV function [26 28]. Moreover, mild impairment in systolic LV function reportedly predicts the risk of adverse CV outcome in dialysis patients [29]. Interestingly, in our cohort, a significant, inverse relationship was shown between LVMi and left ventricular fractional shortening. Moreover, consistent with previous reports in dialysed patients [18], our patients with LV systolic dysfunction showed worse outcome. We observed a direct association between increased PP and LVH, thus confirming the role of arterial stiffness and the consequent increase in velocity of backward reflected waves to the LV in the pathogenesis of cardiac hypertrophy [30]. We cannot rule out that a mild reduction in renal perfusion induced by slightly impaired LV systolic function associated with pathological, highly pulsatile perfusion in the kidney microvasculature as an effect of reduced elasticity of conduit arteries [31] may have played a role in promoting a progressive, further reduction in renal function of patients with pre-existing CKD. Another finding of this study is that increased urinary protein excretion rate did not prove to be a significant predictor of the risk of progression to dialysis in our cohort. We speculate that this might be the consequence of the stronger pathogenetic role played by LVH which possibly masked the effect of proteinuria in predicting adverse renal outcome. Lastly, no predictive role for anaemia was found in our sample. This is consistent with an interventional study that showed neither regression of LVH nor slowing of renal disease progression in CKD patients in whom complete anaemia correction was achieved by epoetin therapy [32]. Of course, some limitations must be acknowledged in our study.
7 676 E. Paoletti et al. First of all, sample size is small, and 10 patients were missed and lost to follow-up. Secondly, there is great heterogeneity in patients age and higher prevalence of men, two factors which may affect LVH in CKD. Furthermore, we have no data concerning the behaviour of LVMi during the observation period, and we did not evaluate the potential role of changes in some predictors and the effect of intervention on such factors during follow-up in counteracting both the progression to ESRD and the risk of death. Lastly, we did not evaluate the role of some potential predictors of adverse outcome in CKD, such as NT-proBNP which reportedly predicts LVH [33], and high-sensitivity C-reactive protein whose association with LVH in CKD however remains controversial [34]. The aim of our study was not to investigate the pathogenesis of LVH in CKD, but its main objective was to assess the impact of cardiac hypertrophy on both CV and renal outcome in CKD patients as compared with well-known risk factors of progression to ESRD and death, namely egfr, proteinuria and arterial hypertension. This is indeed the first long-term observation in CKD patients to point out the pivotal role of LVH in predicting not only the risk of death but also of ESRD requiring dialysis. On the basis of our findings, it is conceivable that LVH agglomerates and encompasses all the potential mechanisms involved in inducing either ESRD or death in patients with overt CKD. Accordingly, systematic assessment of morphology and function of the LV should be considered a key tool in order to obtain prognostic information not only about the CV outcome of CKD patients but also about the progression of their renal disease. This could be especially important in less advanced renal disease patients for whom intervention might still be effective in slowing down progression to the end stage. Conflict of interest statement. None declared. References 1. Hallan SI, Coresh J, Astor BC et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: Stevens PE, O Donoghue DJ, de Lusignan S et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72: Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int 2008; 73: Ishani A, Grandits GA, Grimm RH et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor interventional trial. J Am Soc Nephrol 2006; 17: van der Velde M, Halbesma N, de Charro FT et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol 2009; 20: Hallan SI, Ritz E, Lydersen S et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. JAmSocNephrol 2009; 20: Iseki K, Kinjo K, Iseki C et al. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004; 44: Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and the risk of end-stage renal disease: results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2005; 165: Crowe E, Halpin D, Stevens P. Guideline Development Group. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008; 337: a Paoletti E, Bellino D, Cassottana P et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46: O Brien E, Sheridan J, O Malley K. Dippers and non-dippers. Lancet 1988; 2: National Kidney Foundation: K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43: S1 S Sahn DJ, De Maria A, Kisslo J et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necroscopy findings. Am J Cardiol 1986; 57: Ganau A, Devereux RB, Roman MJ et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11: Levey AS, Greene T, Kusek JWet al. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000; 11: A Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: Paoletti E, Cassottana P, Bellino D et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 2002; 40: Olsen MH, Wachtell K, Borch-Johnsen K et al. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention for Endpoint Reduction. JHumHypertens 2002; 16: Spanaus KS, Kronenberg S, Ritz E et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 2007; 53: Dieplinger B, Mueller T, Kollerits B et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 2009; 75: de Simone G, Kitzman DW, Palmieri V et al. Association of inappropriate left ventricular mass with systolic and diastolic dysfunction. The HyperGEN Study. Am J Hypertens 2004; 17: Drazner MH, Rame JE, Marino EK et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years. The Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: Schrier RW. Role of diminished renal function in cardiovascular mortality. J Am Coll Cardiol 2006; 47: Zoccali C, Benedetto FA, Tripepi G et al. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol 2006; 17: Marchais SJ, Guerin AP, Pannier BM et al. Wave reflections and cardiac hypertrophy in chronic uremia: influence of body size. Hypertension 1993; 22:
8 Salivary testosterone in end-stage renal disease O Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney. Cause and logic of therapy. Hypertension 2005; 46: Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: Khan IA, Fink J, Nass C et al. N-terminal pro-b-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006; 97: Wang AY, Lam CW, Wang M et al. Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrol Dial Transplant 2009; 24: Received for publication: ; Accepted in revised form: Nephrol Dial Transplant (2011) 26: doi: /ndt/gfq439 Advance Access publication 20 July 2010 Salivary testosterone for the diagnosis of androgen deficiency in end-stage renal disease Estela M.L. Cardoso 1,2, Liliana N. Contreras 1,2, Elida G. Tumilasci 3, Alicia Elbert 4, Elvira C. Aguirre 5, Daniel R. Aquilano 6 and Alejandro L. Arregger 1 1 Endocrine Research Department, Instituto de Investigaciones Médicas A. Lanari, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, 2 CONICET, Buenos Aires, Argentina, 3 Laboratory of Salivary Glands, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, 4 CEREHA Dialysis Unit, Buenos Aires, Argentina, 5 Department of Nephrology, Instituto de Investigaciones Médicas A. Lanari, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina and 6 IABE, La Plata, Argentina Correspondence and offprint requests to: Estela M.L. Cardoso; endoexp2000@yahoo.com Abstract Background. Hypogonadism is frequent in patients with end-stage renal disease (ESRD). Salivary testosterone (Sal-T) is a non-invasive tool to screen androgen deficiency in adult male with normal renal function. However, available data on its utility in ESRD are not conclusive. Objectives. The objectives of the study were: (i) to compare free testosterone fractions in saliva (SAL-T) and serum (Free-T); (ii) to establish the correlation of Sal-T with circulating total (TT) and bioavailable testosterone (Bio-T); (iii) to detect androgen deficiency through Sal- T; (iv) to determine the correlation of Sal-T with clinical parameters. Methods. The study included: 60 adult ESRD men on haemodialysis (20 60 years old) with decreased libido referred from two dialysis centres; 112 eugonadic and 40 hypogonadic adult men with normal renal function as controls. Simultaneous morning saliva and serum samples were obtained for testosterone measurements by liquid RIA (SAL-T; TT). Free-T and Bio-T were calculated by the Vermeulen equation. Results. Sal-T(0.338±0.177nM)andFree-T(0.338± nm) did not differ (P > 0.900) in ESRD as well as in control (0.337 ± and ± nm, respectively; P > 0.900). Sal-T levels correlated positively (P < ) with Free-T (r = 0.95), TT (r = 0.80) and Bio-T (r = 0.76) in ESRD. Sal-T negatively correlated with age and years on dialytic therapy. Sal-T showed 100% sensitivity and specificity to differentiate patients with androgen deficiency (22%) from those with normal androgen levels (78%). Hypogonadism was hypergonadotrophic in 69% cases and hypogonadotrophic in 31%. Conclusions. These data demonstrate the value of morning Sal-T testing as a non-invasive approach to screen androgen status in ESRD patients. Keywords: end-stage renal disease; haemodialysis; male androgen deficiency; salivary testosterone; serum testosterone Introduction A number of metabolic and endocrine disorders linked to chronic uraemic syndrome remain a challenge in spite of the progresses in renal disease therapy [1,2]. As reported, two-thirds of men on haemodialysis (HD) have serum testosterone in the hypogonadal range [3,4]. This deficiency The Author Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease?
Nephrol Dial Transplant (2010) 1 of 7 doi: 10.1093/ndt/gfq409 NDT Advance Access published July 13, 2010 Original Article Is left ventricular hypertrophy a powerful predictor of progression to dialysis
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationThe worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey
NDT Advance Access published May 4, 2004 Nephrol Dial Transplant (2004) 1 of 6 DOI: 10.1093/ndt/gfh288 Original Article The worsening of left ventricular hypertrophy is the strongest predictor of sudden
More informationLong-term outcomes in nondiabetic chronic kidney disease
original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationAllopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease
Allopurinol reduces left ventricular hypertrophy and endothelial dysfunction in patients with chronic kidney disease Michelle P Kao, Donald S Ang, Steve Gandy, Chim C Lang, Allan D Struthers Division of
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationHaemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health
Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationArterial Pressure in CKD5 - ESRD Population Gérard M. London
Arterial Pressure in CKD5 - ESRD Population Gérard M. London INSERM U970 Paris 150 SBP & DBP by Age, Ethnicity &Gender (US Population Age 18 Years, NHANES III) 150 SBP (mm Hg) 130 110 80 Non-Hispanic Black
More informationPrevalence of cardiovascular damage in early renal disease
Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract
More informationBlood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods
DIALYSIS Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods Amir Ahamd Nassiri, 1 Legha Lotfollahi, 2,3 Neda Behzadnia, 4 Ilad Alavi Darazam,
More informationBenefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results
European Heart Journal Supplements (2003) 5 (Supplement E), E18 E22 Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results B. Pannier, A.P. Guérin, S.J. Marchais
More informationEchocardiographic assessment of left ventricular hypertrophy in patients of chronic kidney disease
International Journal of Research in Medical Sciences Behera BK et al. Int J Res Med Sci. 2017 Nov;5(11):4783-4788 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20174672
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More information( 1) Framingham Heart
( 1) ( 1) Framingham Heart Study [1] 1. (Am J Kidney Dis. 45: 223-232, 2005) 96 19 1 17 Framingham Heart Study ( 1) American Heart Association (1) (2) (3) (4) [2] (GFR) [3] ARIC [4] Cardiovascular Health
More informationPrevalence of left ventricular hypertrophy in end stage renal disease
368 Prevalence of left ventricular hypertrophy in end stage renal disease Nahida Baigam 1, Musleh Uddin Kalar 2*, Saeeda Fouzia Qasim 3, Arfa Saeed 4, Harris Alvi 5 1 Dept of Nephrology Abbasi Shaheed
More informationAortic stenosis (AS) is common with the aging population.
New Insights Into the Progression of Aortic Stenosis Implications for Secondary Prevention Sanjeev Palta, MD; Anita M. Pai, MD; Kanwaljit S. Gill, MD; Ramdas G. Pai, MD Background The risk factors affecting
More informationMasatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health
176 J Occup Health, Vol. 54, 2012 J Occup Health 2012; 54: 176 180 Journal of Occupational Health Evaluation of Validity of the Urine Dipstick Test for Identification of Reduced Glomerular Filtration Rate
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationMasked Hypertension and Aortic Coarctation: Impact on Ventricular Function and Morphology
Masked Hypertension and Aortic Coarctation: Impact on Ventricular Function and Morphology Giovanni Di Salvo MD, PhD, MMSc, FESC BACKGROUND MASKED HYPERTENSION Masked hypertension (MH) consists of an elevated
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationDoes the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy?
(24) 18, S23 S28 & 24 Nature Publishing Group All rights reserved 95-92/4 $3. www.nature.com/jhh ORIGINAL ARTICLE Does the reduction in systolic blood pressure alone explain the regression of left ventricular
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationLong-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained?
O R I G I N A L A R T I C L E Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? H. Borsboom 1#, L. Smans 1#, M.J.M.
More information23-Jun-15. Albuminuria Renal and Cardiovascular Consequences A history of progress since ,490,000. Kidney Center, UMC Groningen
Kidney function (egfr in ml/min) Albuminuria (mg/hr) Incidentie ESRD (%) 3-Jun- Number of patients worldwide that receives kidney replacement therapy Albuminuria Renal and Cardiovascular Consequences A
More informationComparison of 44-Hour and Fixed 24-Hour Ambulatory Blood Pressure Monitoring in Dialysis Patients
ORIGINAL PAPER Comparison of 44-Hour and Fixed 24-Hour Ambulatory Blood Pressure Monitoring in Dialysis Patients Wenjin Liu, MD; Hong Ye, MD; Bing Tang, MD; Zhiping Sun, MD; Ping Wen, MD; Wenhui Wu, MD;
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationReview of Cardiac Imaging Modalities in the Renal Patient. George Youssef
Review of Cardiac Imaging Modalities in the Renal Patient George Youssef ECHO Left ventricular hypertrophy (LVH) assessment Diastolic dysfunction Stress ECHO Cardiac CT angiography Echocardiography - positives
More informationMareomi Hamada, Go Hiasa, Osamu Sasaki, Tomoaki Ohtsuka, Hidetoshi Shuntaro Ikeda, Makoto Suzuki, Yuji Hara, and Kunio Hiwada
297 Original Article Serum Creatinine Level Renal Involvement Essential Underestimates Hypertensive in Elderly Patients with Hypertension Yuji Shigematsu, Mareomi Hamada, Go Hiasa, Osamu Sasaki, Tomoaki
More informationBeta-blockers for coronary heart disease in chronic kidney disease
Nephrol Dial Transplant (2008) 23: 2274 2279 doi: 10.1093/ndt/gfm950 Advance Access publication 10 January 2008 Original Article Beta-blockers for coronary heart disease in chronic kidney disease Michel
More informationEchocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?
Journal of Human Hypertension (1999) 13, 505 509 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Echocardiographic definition of left ventricular
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Nephrology
More informationInteraction between GFR and Risk Factors for Morbidity and Mortality in African Americans with CKD
Article Interaction between GFR and Risk Factors for Morbidity and Mortality in African Americans with CKD Kevin F. Erickson,* Janice Lea, and William M. McClellan Summary Background and objectives The
More informationCentral blood pressure variability is increased in hypertensive patients with target organ damage
Received: 30 August 2017 Revised: 7 October 2017 Accepted: 20 October 2017 DOI: 10.1111/jch.13172 ORIGINAL PAPER Central blood pressure variability is increased in hypertensive patients with target organ
More informationEarly Detection of Damaged Organ
Early Detection of Damaged Organ Regional Cardiovascular Center, Chungbuk National University Kyung-Kuk Hwang Contents NICE guideline 2011 - Confirm the diagnosis of HT ambulatory blood pressure monitoring
More informationLEFT VENTRICULAR HYPERTROPHY AND CLINICAL OUTCOME IN CAPD PATIENTS
Peritoneal Dialysis International, Vol. 20, pp. 461 466 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2000 International Society for Peritoneal Dialysis LEFT VENTRICULAR HYPERTROPHY
More informationProf. Armando Torres Nephrology Section Hospital Universitario de Canarias University of La Laguna Tenerife, Canary Islands, Spain.
Does RAS blockade improve outcomes after kidney transplantation? Armando Torres, La Laguna, Spain Chairs: Hans De Fijter, Leiden, The Netherlands Armando Torres, La Laguna, Spain Prof. Armando Torres Nephrology
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationSOME NOVEL BIOMARKERS OF CARDIOVASCULAR DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE
SOME NOVEL BIOMARKERS OF CARDIOVASCULAR DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE Dept. of nephrology, Clinic for internal medicine University Medical Centre Maribor Faculty of Medicine, University
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationD Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis
Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis,
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationAssessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time. Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France
Assessment of Arterials Functions: Is Pulse Wave Velocity ready forprime Time Gérard M. LONDON INSERM U970 Hopital Georges Pompidou Paris, France The causes of Cardiovascular Diseases in CKD Systolic BP;
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationEffects of Renin-Angiotensin System blockade on arterial stiffness and function. Gérard M. LONDON Manhès Hospital Paris, France
Effects of Renin-Angiotensin System blockade on arterial stiffness and function Gérard M. LONDON Manhès Hospital Paris, France Determinants of vascular overload (afterload) on the heart Peripheral Resistance
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationAmbulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Rajiv Agarwal, MD
Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease Rajiv Agarwal, MD Summary: Hypertension is an important risk factor for adverse cardiovascular and renal outcomes, particularly
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationAttivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi
Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Mario Cozzolino, MD, PhD, FERA Dipartimento di Scienze della Salute Università di Milano UO Nefrologia e Dialisi Laboratorio
More informationEvidence-based practice in nephrology : Meta-analysis
Evidence-based practice in nephrology : Meta-analysis Paweena Susantitaphong, MD,Ph.D 1-3 1 Associate Professor, Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn
More informationDIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI.
DIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI. Franco Cipollini, Carlo Porta, Enrica Arcangeli, Carla Breschi, & Giuseppe Seghieri Azienda USL 3, Ambulatorio
More informationReport and Opinion 2016;8(12)
Prevalence of calcific aortic valve stenosis in haemodialysis patients at AL Hussein University Hospital. Ahmed Alaa Saad 1, Sami H. Nooh 2, Osama A. Khamis 1, Magdy E. Mohamed 1, Mohamed Abdelhafez 1
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationNumerous epidemiologic studies have shown an association
SYMPOSIUM ARTICLE Cardiorenal Risk Factors Barry M. Wall, MD Abstract: The chronic renocardiac syndrome, in which chronic kidney disease (CKD) contributes to impairment of cardiac function or structure,
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationPlasma MR-proADM is superior to NTproBNP for all-cause short term mortality prediction in acute pulmonary embolism.
J. Pedowska-Wloszek, M. Kostrubiec, A. Labyk, S. Pacho, O. Dzikowska-Diduch, P. Bienias, B. Lichodziejewska, P. Palczewski, M. Ciurzynski, P. Pruszczyk Plasma MR-proADM is superior to NTproBNP for all-cause
More informationANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*
Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical
More informationEnd stage renal disease (ESRD) is the irreversible deterioration of renal function
28 Journal of the association of physicians of india JANUARY 2014 VOL. 62 Original Article Echocardiographic Assessment of Cardiac Dysfunction in Patients of End Stage Renal Disease on Haemodialysis Mukesh
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationImproved survival of type 2 diabetic patients on renal replacement therapy in Finland
Nephrol Dial Transplant (2010) 25: 892 896 doi: 10.1093/ndt/gfp555 Advance Access publication 21 October 2009 Improved survival of type 2 diabetic patients on renal replacement therapy in Finland Marjo
More informationLEFT VENTRICULAR HYPERTROPHY IN AFRICAN BLACK PATIENTS WITH CHRONIC RENAL FAILURE AT FIRST EVALUATION
LEFT VENTRICULAR HYPERTROPHY IN AFRICAN BLACK PATIENTS WITH CHRONIC RENAL FAILURE AT FIRST EVALUATION Objective: Chronic kidney disease (CKD) is a major cause of cardiovascular morbidity and mortality
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationBiomarkers in the Assessment of Congestive Heart Failure
Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial
More informationForty-four-hour interdialytic ambulatory blood pressure monitoring and cardiovascular risk in pediatric hemodialysis patients
Clin Kidney J (2014) 7: 33 39 doi: 10.1093/ckj/sft149 Advance Access publication 23 December 2013 Original Article Forty-four-hour interdialytic ambulatory blood pressure monitoring and cardiovascular
More informationThe most common cause of death among hemodialysis
Diagnosis of Acute Myocardial Infarction in Hemodialysis Patients With High-Sensitivity Cardiac Troponin T Assay Hua-Lan Huang, MM; Shuai Zhu, MM; Wei-Qing Wang, MM; Xin Nie, MM; Ying-Ying Shi, MD; Yong
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationThe relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan
Environ Health Prev Med (2011) 16:191 195 DOI 10.1007/s12199-010-0183-9 SHORT COMMUNICATION The relation between estimated glomerular filtration rate and proteinuria in Okayama Prefecture, Japan Nobuyuki
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More information